Personalized Cell Therapy Market - Insights
Individualized treatment for various diseases such as cancer and autoimmune diseases by injecting living cells into a patient’s body is known as personalized cell therapy. It has various applications such as platelet transfusions, bone marrow transplantation, whole blood transfusions, packed red cell transfusions, and organ transplantation. It is used to treat various chronic conditions such as Parkinson’s disease and amyotrophic lateral sclerosis (neurological diseases), spinal cord injuries, diabetes, and cancer.
The global personalized cell therapy market was valued at US$ 8,046.30 million in 2018 and is expected to exhibit a CAGR of 23.5% during the forecast period (2019 – 2027).
Figure 1. Global Personalized Cell Therapy Market Size Analysis (US$ Mn) and Forecast and Absolute $ Opportunity
Source: Coherent Market Insights Analysis (2019)
Increased economic burden due to neurological disorders is expected to fuel the global personalized cell therapy market growth
There are several studies conducted on stem cell or personalized cell therapy candidates to treat neurological disorder and spinal cord injury. For instance, in September 2016, MAPFRE Foundation, announced its first clinical trial results of personalized cell therapy in patients with complete and chronic spinal cord injury. The study was conducted to implant mesenchymal stem cells, which can create different types of tissue to treat spinal cord injury.
Increasing development of personalized cell therapy products along with high prevalence of lifestyle diseases is driving the global personalized cell therapy market growth
Rising prevalence of chronic diseases and increasing incidence of cancer is expected to fuel growth of the global personalized cell therapy market over the forecast period. For instance, according to the National Cancer Institute (NCI), in 2016, there were an estimated 15.5 million cancer cases that have been reported in the U.S. Moreover, according to NCI, in 2017, around 15,270 children and adolescents of age group of 0 to 19 were diagnosed with cancer in the U.S. Furthermore, according to the International Diabetes Federation (IDF), in 2017, over 425 million adults suffered from diabetes globally, and this is expected to reach 629 million by 2045.
Manufacturers are conducting large number clinical trials, in order to develop novel personalized cell therapies targeting chronic diseases such as cancer, diabetes, and other autoimmune diseases. For instance, in April 2019, Orgenesis Inc. a developer, and service provider of advanced cell therapies received Institutional Review Board (IRB) approval to collect liver biopsies from patients at Rambam Medical Center located in Haifa, Israel. The sample will be collected to confirm the safety and efficacy of liver cells for personalized cell replacement therapy in the patients with insulin-dependent diabetes resulting from total or partial pancreatectomy. Thus, increasing research studies is expected to drive the global personalized cell therapy market growth.
Global Personalized Cell Therapy Market- Regional Analysis
Regional segmentation of the global personalized cell therapy market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
Better healthcare amenities along with high adoption of new technology for the treatment of chronic disease such as cancer, diabetes, renal dysfunction, and other autoimmune diseases in the developed economies is expected to boost overall sales of personalized cell therapy products, which in turn expected to drive the personalized cell therapy market growth over the forecast period. Moreover, number of research institutes in North America region are engaged in development of novel personalized cell therapy for various indications. For instance, in June 2019, University of Wisconsin’s (UW) Program for Advanced Cell Therapy (PACT) launched First-in-U.S. Cell Therapy Trial to treat a viral infection faced by kidney and/or pancreas transplant recipients.
Increasing approval for personalized cell therapy in Asia Pacific region is expected to boost the personalized cell therapy market growth. For instance, in February 2019, Ministry of Health, Labour and Welfare, Japan, approved production and sales of a CAR T-cell therapy, Kymriah therapy developed by Swiss pharmaceutical (Novartis), for treatment of the patients (young) with leukemia. Moreover in February 2019, Ministry of Health, Labour and Welfare, Japan, approved human induced pluripotent stem cells therapy trial to treat spinal cord injury. The trial was initiated by the researchers of Keio University in 2019.
Expansion of manufacturing facility for the increased production of personalized cell therapy in the U.K. is anticipated to witness the personalized cell therapy market growth in European region. For instance, in 2018, according to the Cell and Gene Therapy (CGT) Catapult report on U.K.’s cell and gene therapy industry, the U.K. has accounted for 60% increase in manufacturing space for personalized cell therapy developing, licensed by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) and meeting Good Manufacturing Practice (GMP) standards
Figure 2. Global Personalized Cell Therapy Market Value Analysis, By Region - 2018
Source: Coherent Market Insights (2019)
Market players operating in the global personalized cell therapy market include Cytori Therapeutics Inc., Bellicum Pharmaceuticals, Inc., Saneron CCEL Therapeutics, Inc., MolMed S.p.A., Vericel Corporation, Novartis AG, Gilead Sciences, Inc., Celgene Corporation, Bluebird Bio, Inc. and Aurora Biopharma Inc.
Frequently Asked Questions